Abstract
Objective. The Outcome Measures in Rheumatology (OMERACT) Filter 2.0 framework was developed in 2014 to aid core outcome set development by describing the full universe of “measurable aspects of health conditions” from which core domains can be selected. This paper provides elaborations and updated concepts (OMERACT Filter 2.1).
Methods. At OMERACT 2018, we discussed challenges in the framework application caused by unclear or ambiguous wording and terms and incompletely developed concepts.
Results. The updated OMERACT Filter 2.1 framework makes benefits and harms explicit, clarifies concepts, and improves naming of various terms.
Conclusion. We expect that the Filter 2.1 framework will improve the process of core set development.
Footnotes
DEB, COB III, PGC, MAD, MPD, LG, LM, LS, JAS, VS, GAW, and PT are members of the executive of OMERACT, an organization that develops outcome measures in rheumatology and receives arms-length funding from 12 companies. PGC is funded in part by the NIHR Leeds Biomedical Research Centre. The views expressed in this article are those of the authors and not necessarily those of the UK National Health Service, the NIHR, or the Department of Health. JAS is supported by the resources and use of the facilities at the VA Medical Center at Birmingham, Alabama, USA. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the US government. LM is a principal investigator on the Australian Rheumatology Association Database, which has received arms-length funding from Pfizer Australia, AbbVie Australia, Eli Lilly Australia, and Janssen Australia.
- Accepted for publication December 6, 2018.